← All trials
NCT01562132
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2013
- Primary completion
- Jul 1, 2014
- Completion date
- Jul 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yale UniversityLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Kenya Medical Research InstituteCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of NairobiOverall official - principal investigator
- University of NairobiCollaborator
- Bausch Health CompaniesCollaborator
- Yale UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.